BioMarin and Ascendis sign settlement and license agreement over CNP patentsSep 30PartnershipBiomarin Pharmaceutical Inc
BioMarin and Ascendis settle global patent dispute over YuviwelAug 31PartnershipAscendis Pharma A/SBiomarin Pharmaceutical Inc
Ascendis Pharma posts Q2 2026 revenue of €315 million, up 105% year over yearAug 13Clinical readoutAscendis Pharma A/Snavepegritide
Sign inSign in